Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors
Taiki Hakozaki, Takuma Matsuo, Akihiro Shimizu, Yoko Ishihara, Yukio Hosomi
Topics & Concepts
MedicinePolypharmacyInternal medicineLung cancerConcomitantProportional hazards modelTyrosine-kinase inhibitorOncologyMultivariate analysisOdds ratioClinical significanceCancerLung Cancer Treatments and MutationsChronic Myeloid Leukemia TreatmentsChemotherapy-induced cardiotoxicity and mitigation